Abstract:Diabetic kidney disease (DKD) is the worldwide leader in end-stage kidney failure and has limited treatment options. Cellular senescence abundance and inflammation contribute to DKD pathogenesis. We previously demonstrated that activin A, an inflammatory mediator of pro-fibrotic kidney injury and cellular senescence, is increased in DKD and correlates with DKD injury and kidney function. We hypothesized that activin A contributes to DKD injury causing pro-fibrotic, pro-inflammatory, and cellular senescence effects in vitro, and that antagonism of activin A is achieved with follistatin. An in vitro model of DKD injury was applied with high-glucose (HG) and transforming growth factor-β (TGFβ) exposure for 24 hours in U-937-derived macrophages and renal epithelial (HK2) cells. Prior to exposure, U-937 cells were converted to M0 macrophages with phorbol myristate acetate (PMA). To examine the potential of reducing activin A release by DKD injured cells, follistatin, an activin A antagonist, was added to the media of cells at the time of injury for 24 hours. Additionally, an activin A neutralizing antibody was added to the collected supernatant of DKD injured cells. Activin A, senescence (p16), pro-fibrotic (collagen I), and pro-inflammatory (monocyte chemoattractant protein [MCP]-1, tumor necrosis factor [TNF]-alpha, interleukin [IL]-6) markers were measured through qPCR, ELISA (activin A), and immunofluorescence staining (activin A). DKD injury in renal epithelial cells increased protein expression of activin A, increased gene expression of activin A, p16, and collagen I, but did not significantly increase MCP-1 expression at 24 hour exposure (Figure 1). Furthermore, DKD injury led to increased activin A release in conditioned medium vs. control renal epithelial cells. Administration of follistatin reduced activin A release by renal epithelial cells. Application of neutralizing antibody reduced activin A levels in collected medium after cell injury. After DKD injury in U-937 derived macrophages, activin A gene expression was increased. Injured macrophages had increased gene expression of TNF-alpha and IL-6, demonstrating a pro-inflammatory phenotype. In conclusion, diabetic kidney injury increases activin A release, inflammation markers, and senescence markers in kidney cells and macrophages, therein contributing to downstream effects that further propagate disease. As shown, follistatin antagonism reduces activin A release by injured cells. Additional studies are needed to explore activin A as a promising therapeutic target and follistatin as a possible treatment in DKD. NIH 5TL1TR002380-07, AG076537, DK123492, DK109134. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B

Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling

Activin receptor type 2A (ACVR2A) functions directly in osteoblasts as a negative regulator of bone mass

Functional Antagonism Between Activin And Osteogenic Protein-1 In Human Embryonal Carcinoma Cells

Activin A induces a non-fibrotic phenotype in smooth muscle cells in contrast to TGF-β

Activin E is a TGFβ ligand that signals specifically through activin receptor-like kinase 7

Activin E is a transforming growth factor β ligand that signals specifically through activin receptor-like kinase 7

Activin A promotes the development of acquired heterotopic ossification and is an effective target for disease attenuation in mice

Regulation of Cell Proliferation, Apoptosis, and Carcinogenesis by Activin

Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects.

Activin receptor antagonists for cancer-related anemia and bone disease

Engagement of Activin and Bone Morphogenetic Protein Signaling Pathway Smad Proteins in the Induction of Inhibin B Production in Ovarian Granulosa Cells.

Constitutive Activation of Activin Receptor-like Kinase 2 in Human Breast Cancer Cells inhibits Metastatic Progression and Osteolytic Bone Lesions

Anti-Human Activin Receptor-Like Kinase 1 (alk1) Antibody Attenuates Bone Morphogenetic Protein 9 (Bmp9)-Induced Alk1 Signaling and Interferes with Endothelial Cell Sprouting

Activin A more prominently regulates muscle mass in primates than does GDF8

Two Activin Type 2B Receptors from Sea Bream Function Similarly in vitro

Activin A Contribution to Diabetic Kidney Disease Injury and Effects of Activin A Antagonism In-Vitro

Immunoregulation by members of the TGFβ superfamily

Phosphorylation regulation of the interaction between Smad7 and activin type I receptor.

Pathological insights into activin A: Molecular underpinnings and therapeutic prospects in various diseases

Activin A regulation of gonadotropin-releasing hormone synthesis and release in vitro